From LinkedIn: The Dragon Amongst ACE Market IPO - Alpha IVF
Entering 2024, Alpha IVF Group Berhad is emerging as a noteworthy company, poised to make its debut on the stock market. This development is not just another IPO; it signifies the entry of Malaysia’s second company, after another listed on the LEAP market, to specialize in assisted reproductive services. With a focus on providing hope to couples facing infertility challenges, Alpha IVF stands out for its advanced in vitro fertilization (IVF) and other reproductive technologies.
Rumors suggest that Alpha IVF’s post-IPO valuation could fetch over RM1.0 billion, potentially marking it as one of the largest IPOs in the ACE market segment in recent years. Such anticipation is fueled by the company’s impressive financial performance, with Profit After Tax (PAT) margins showing substantial growth over recent fiscal periods, highlighting the company’s operational efficiency and profitability.
Alpha IVF’s financial resilience is evident from its escalating PAT margins, which have outperformed many in the tech sector. With figures rising from 3.71% in FYE2021 to an astonishing 43.59% in FPE2023 (9 months), the company’s profitability trajectory is impressive. However, the sustainability of these margins remains a focal point of interest as the official prospectus is awaited, with many fund managers keenly observing.
Post-IPO, Alpha IVF intends to uphold a generous dividend payout ratio of 60.0%, promising a substantial return to its shareholders. This strategy underscores the company’s confidence in its cash-generative business model, which relies more on expertise than on heavy asset investments. Furthermore, Alpha IVF’s expansion plans include extending its footprint to Indonesia and potentially Cambodia or Laos, alongside establishing a sales center in China to tap into the burgeoning medical tourism sector.
At the heart of Alpha IVF’s success is its comprehensive approach to understanding and addressing the unique needs of its clients. From assessing sperm and ova health to pioneering techniques in ovarian stimulation and cryopreservation, the company stands at the forefront of reproductive technology. Alpha IVF’s services extend beyond traditional IVF, incorporating advanced procedures like Preimplantation Genetic Testing (PGT) to enhance success rates and reduce genetic risks.
In an era where technology intersects with healthcare, Alpha IVF leverages AI to select embryos with higher chances of successful implantation, further refining its service offerings. The company also explores innovative treatments like Ova-PRP to improve ovarian health, showcasing its commitment to advancing reproductive technologies.
With declining birth rates and changing societal attitudes towards parenthood, IVF services like those offered by Alpha IVF may become increasingly sought after, presenting a compelling narrative for investors and industry observers alike.
Their GP margin looks very "nice" comparing to others competitors, not excluding what auditors have done on it, but it's kind of obvious. Also, reminding that there are TONs of share offered in the IPO.
This is a only n niche market ipo. U can see ipo in technology n construction or plantstion sector often. Bt science technology alpha is the only one in years to come. Ipo is closed. So say what good also no point. Wait for it to be listed than everyone will know. I say will up 50% or more. Maybe limit up.
Alpha IVF Group Bhd (0303) fertility care specialist and one of the largest listing on the ACE Market of Bursa Malaysia today.
Oversubscribed by 2.73x at an IPO price of RM0.32 with a market capitalisation of RM1.55 billion.
It is raising RM116.6 million from this listing exercise - business expansion, setting up new in vitro fertilisation (IVF) centres, satelite clinics, sales offices and upgrading of existing specialist centres, facilities and offices.
It has attracted eight cornerstone investors namely; abrdn Malaysia, AHAM Asset Management, AIA Bhd, Eastspring Investments Bhd, Hong Leong Asset Management Bhd, Kenanga Investors Bhd, Lion Global Investors Ltd, and Value Partners Hong Kong Ltd.
Alpha IVF group managing director Datuk Dr Colin Lee Soon Soo said their 2QFY2024 financial performance highlights the group’s ability to ride the wave of medical tourism and growing need for IVF treatments.
It reported a net profit of RM12.21 million and RM38.54 million in revenue for 2QFY24. For the cumulative six months ended Nov 30, 2023, Alpha IVF posted a net profit of RM25.34 million, on the back of revenue of RM80.14 million.
RHB Investment Bank, Public Investment Bank, Mercury Securities, TA Securites and Rakuten Trade have given a target prices of between RM0.28 - RM0.40
There will always be trading opportunities on listing day.
Sell call alpha 32 cents Tp 24-27 cents Let see 1 month time how it look like.but doubt will up as number of shares over 4 billion not over 400 million. 22/3/24 6.20pm
hah just sold all and made a quick 1.6% profit for holding it for 2 days. a nice 5 course tai chow dinner tonight. this stock is a potential sleeper, spoilt by substantial shareholders selling on first day causing retailers to panic for no reason. had wanted to keep this in portfolio but too bad, selfish then all lose lose together
A bit overvalued, but in a future-ready and future-proof industry. These services are going to be more common by the year given the declining fertility.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
ronnie2u
667 posts
Posted by ronnie2u > 2024-03-04 13:58 | Report Abuse
From LinkedIn:
The Dragon Amongst ACE Market IPO - Alpha IVF
Entering 2024, Alpha IVF Group Berhad is emerging as a noteworthy company, poised to make its debut on the stock market. This development is not just another IPO; it signifies the entry of Malaysia’s second company, after another listed on the LEAP market, to specialize in assisted reproductive services. With a focus on providing hope to couples facing infertility challenges, Alpha IVF stands out for its advanced in vitro fertilization (IVF) and other reproductive technologies.
Rumors suggest that Alpha IVF’s post-IPO valuation could fetch over RM1.0 billion, potentially marking it as one of the largest IPOs in the ACE market segment in recent years. Such anticipation is fueled by the company’s impressive financial performance, with Profit After Tax (PAT) margins showing substantial growth over recent fiscal periods, highlighting the company’s operational efficiency and profitability.
Alpha IVF’s financial resilience is evident from its escalating PAT margins, which have outperformed many in the tech sector. With figures rising from 3.71% in FYE2021 to an astonishing 43.59% in FPE2023 (9 months), the company’s profitability trajectory is impressive. However, the sustainability of these margins remains a focal point of interest as the official prospectus is awaited, with many fund managers keenly observing.
Post-IPO, Alpha IVF intends to uphold a generous dividend payout ratio of 60.0%, promising a substantial return to its shareholders. This strategy underscores the company’s confidence in its cash-generative business model, which relies more on expertise than on heavy asset investments. Furthermore, Alpha IVF’s expansion plans include extending its footprint to Indonesia and potentially Cambodia or Laos, alongside establishing a sales center in China to tap into the burgeoning medical tourism sector.
At the heart of Alpha IVF’s success is its comprehensive approach to understanding and addressing the unique needs of its clients. From assessing sperm and ova health to pioneering techniques in ovarian stimulation and cryopreservation, the company stands at the forefront of reproductive technology. Alpha IVF’s services extend beyond traditional IVF, incorporating advanced procedures like Preimplantation Genetic Testing (PGT) to enhance success rates and reduce genetic risks.
In an era where technology intersects with healthcare, Alpha IVF leverages AI to select embryos with higher chances of successful implantation, further refining its service offerings. The company also explores innovative treatments like Ova-PRP to improve ovarian health, showcasing its commitment to advancing reproductive technologies.
With declining birth rates and changing societal attitudes towards parenthood, IVF services like those offered by Alpha IVF may become increasingly sought after, presenting a compelling narrative for investors and industry observers alike.